On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles
Small · 2025
DOI: 10.1002/smll.202500114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Shai Zilberzwige-Tal und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, 6997801, Israel. Hauptthemen laut MEDLINE: Nanoparticles, mRNA Vaccines, Lab-On-A-Chip Devices, Lipids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
RNA‐based therapeutics have revolutionized precision medicine due to their unprecedented potency, specificity, and adaptability. However, the inherent limited stability of RNA, including mRNA used in vaccines, is a major obstacle to the full realization of their potential. This instability, coupled with the centralized nature of vaccine production, currently limits the generation of RNA therapeutics at the point of care, which will otherwise fully harness the potential of these agents. Here, a microfluidic platform is presented for on‐demand, personalized synthesis of modified mRNA stabilized by lipid nanoparticles. The design includes trapped biotinylated DNA, tagged T7 RNA polymerase, and a Tesla mixer, allowing the on‐chip synthesis, purification, and encapsulation of mRNA in uniform lipid nanoparticles (LNPs), all conducted seamlessly on the same microfluidic device. This on‐chip microfluidic synthesis approach is found to match standardized mRNA production yields, yet surpasses typical purification methods. Furthermore, as a proof‐of‐concept, the versatility and efficacy of the platform are demonstrated by generating diverse RNA sequences and structures, exhibiting functionality in human cell lines and mouse models. Moreover, an active SARS‐CoV‐2 vaccine is successfully engineered, highlighting the platform's potential for personalized vaccination strategies and offering a promising avenue for high throughput, decentralized vaccine delivery, reduced cold chain dependence, and even advancing current personalized medicine approaches through custom RNA therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, 6997801, Israel.
- Yusuf Hamied Department of Chemistry, Centre for Misfolding Diseases, University of Cambridge, Cambridge, CB2 1EW, UK.
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, 76100, Israel.
- Department of Materials Science and Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
- The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, 6997801, Israel.
ORCID-Profile: Shai Zilberzwige-Tal, Aviad Levin, Gal Finkelstein-Zuta, Topaz Kreiser, Lihi Gershon, Meir Goldsmith, Edo Kon, Yoav Navon, Ofer Cohen, Tuomas Pj Knowles, Dan Peer, Ehud Gazit
Zitieren
APA
Zilberzwige-Tal, S., Levin, A., Ezra, A., Elia, U., Finkelstein-Zuta, G., Kreiser, T., Gershon, L., Goldsmith, M., Kon, E., Navon, Y., Cohen, O., Knowles, T. P., Peer, D., & Gazit, E. (2025). On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles. Small. https://doi.org/10.1002/smll.202500114
Vancouver
Zilberzwige-Tal S, Levin A, Ezra A, Elia U, Finkelstein-Zuta G, Kreiser T, et al. On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles. Small. 2025. doi:10.1002/smll.202500114
BibTeX
@article{ZilberzwigeTal2025,
author = {Zilberzwige-Tal, Shai and Levin, Aviad and Ezra, Assaf and Elia, Uri and Finkelstein-Zuta, Gal and Kreiser, Topaz and Gershon, Lihi and Goldsmith, Meir and Kon, Edo and Navon, Yoav and Cohen, Ofer and Knowles, Tuomas Pj and Peer, Dan and Gazit, Ehud},
title = {On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202500114}
}
EUVIMED